Bank of America just raised its EUR/USD forecast
William Lewis (JO:LEWJ), the Chair and CEO of Insmed Inc (NASDAQ:INSM), executed a series of stock transactions on February 18, 2025, according to a recent SEC filing. Lewis sold shares totaling approximately $2.07 million, with sale prices ranging from $79.95 to $81.81 per share. The transactions occurred as INSM trades near its 52-week high of $83.89, with the stock showing remarkable strength, gaining nearly 187% over the past year. According to InvestingPro analysis, the company currently appears overvalued based on its Fair Value metrics.
The transactions, conducted under a pre-established 10b5-1 trading plan, involved multiple sales of common stock. A significant portion of the sales included 16,743 shares sold at an average price range of $80.50 to $81.43, and 6,074 shares sold at prices between $80.51 and $81.42. With a market capitalization of $15 billion and analyst price targets ranging from $67.26 to $107, InvestingPro subscribers can access detailed insider trading analysis and 13 additional exclusive insights about INSM.
In addition to the sales, Lewis also exercised stock options, acquiring a total of 25,580 shares with exercise prices ranging from $10.85 to $22.76. These transactions were part of a broader strategy to manage his holdings in Insmed, a pharmaceutical company based in Bridgewater, New Jersey.
Following these activities, Lewis holds direct and indirect ownership of several shares through various trusts, reflecting his ongoing involvement with the company.
In other recent news, Insmed Inc. reported its fourth-quarter 2024 earnings, revealing a larger-than-expected loss per share while exceeding revenue forecasts. The company posted an earnings per share (EPS) of -1.32, missing the anticipated -1.18, but its revenue reached $104.44 million, surpassing the forecasted $97.68 million. Insmed experienced a robust 19% year-over-year growth in global net revenue for 2024, driven significantly by contributions from the U.S. and Japan. The company has set a 2025 revenue guidance for ARIKAYCE between $405 million and $425 million, anticipating significant milestones, including the potential launch of brensocatab in Q3 2025.
Additionally, Insmed’s strategic focus on expanding its sales force and preparing for new product launches has positioned it well in the competitive biotech landscape. Despite the EPS miss, the revenue beat by 6.9% suggests strong sales performance, potentially mitigating some concerns over profitability. The company holds cash, cash equivalents, and marketable securities amounting to $1.4 billion, underscoring a solid financial footing. Analysts have shown interest in Insmed’s market access strategy and the anticipated impact of the brensocatab launch, with management emphasizing preparedness for a smooth market entry. The company also anticipates key data readouts for its pipeline drugs, which could drive future growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.